CA2281789A1 - Topical nasal antiinflammatory compositions - Google Patents
Topical nasal antiinflammatory compositions Download PDFInfo
- Publication number
- CA2281789A1 CA2281789A1 CA002281789A CA2281789A CA2281789A1 CA 2281789 A1 CA2281789 A1 CA 2281789A1 CA 002281789 A CA002281789 A CA 002281789A CA 2281789 A CA2281789 A CA 2281789A CA 2281789 A1 CA2281789 A1 CA 2281789A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- agent
- group
- nasal
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of an antiinflammatory agent and a therapeutically effective amount of at least one agent selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anticholinergic agent, an anesthetic and a mucolytic agent. The present compositions are useful as nasal sprays and nose drops for the treatment of nasal and sinus conditions.
Description
TOPICAL NASAL ANTIINFLAMMATORY
COMPOSITIONS
SPECIFICATION
BACKGROUND OF THE INVENTION
Topical nasal antiinflammatory preparations are known in the art for s the treatment of inflammatory conditions of the nasal mucous membranes, and in particular for relief of the symptoms of nasal and sinus conditions such as rhinitis.
However, nasal and sinus conditions may be characterized by diverse symptoms requiring treatment with multiple therapeutic agents. For example, allergic rhinitis may be characterized by rhinorrhea, nasal itching, sneezing, congestion and postnasal io drip and treatment may require antihistamines, decongestants, antiallergics and anesthetics in addition to antiinflammatories.
The use of multiple topical nasal preparations to administer multiple therapeutic agents suffers from significant disadvantages. The volume of liquid that can effectively be applied nasally is limited by the surface area of the nostril and the bioadhesiveness of the liquid. In addition, a sufficient contact time between topical preparations and the surface area of the nostril is required to assure adequate dosing of a therapeutic agent. Further, spray formulations require a threshold surface tension to form droplets. Accordingly, the delivery volume per actuation is limited to the volume that will be retained in the nostril without premature drainage.
Thus 2o multiple topical nasal preparations cannot be effectively administered simultaneously.
COMPOSITIONS
SPECIFICATION
BACKGROUND OF THE INVENTION
Topical nasal antiinflammatory preparations are known in the art for s the treatment of inflammatory conditions of the nasal mucous membranes, and in particular for relief of the symptoms of nasal and sinus conditions such as rhinitis.
However, nasal and sinus conditions may be characterized by diverse symptoms requiring treatment with multiple therapeutic agents. For example, allergic rhinitis may be characterized by rhinorrhea, nasal itching, sneezing, congestion and postnasal io drip and treatment may require antihistamines, decongestants, antiallergics and anesthetics in addition to antiinflammatories.
The use of multiple topical nasal preparations to administer multiple therapeutic agents suffers from significant disadvantages. The volume of liquid that can effectively be applied nasally is limited by the surface area of the nostril and the bioadhesiveness of the liquid. In addition, a sufficient contact time between topical preparations and the surface area of the nostril is required to assure adequate dosing of a therapeutic agent. Further, spray formulations require a threshold surface tension to form droplets. Accordingly, the delivery volume per actuation is limited to the volume that will be retained in the nostril without premature drainage.
Thus 2o multiple topical nasal preparations cannot be effectively administered simultaneously.
Another disadvantage of the administration of multiple topical nasal preparations is patient inconvenience. Patient compliance may be compromised by the inconvenience of applying multiple spray products or nose drops. Patients complain when excess spray drains into their throats where it can be tasted, resulting s in a need for flavor masking of bitter medicaments.
Accordingly, a need exists for a convenient means of nasal administration of multiple therapeutic agents.
SUMMARY OF THE INVENTION
to The present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, an anticholinergic agent, a leukotriene inhibitor, an ~s antihistamine, an antiallergic agent, an anesthetic, and a mucolytic agent.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides topically applicable nasal compositions comprising a topical antiinflammatory agent and at least one additional therapeutic 2o agent. The present compositions are useful for the treatment of nasal and sinus conditions, for example allergic rhinitis or the common cold.
The topical antiinflammatory agents in the compositions of the present invention are corticosteroids known in the art to suppress inflammation. In a preferred embodiment the topical antiinflammatory agent is beclomethasone 2s diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate or triamcinolone acetonide. The compositions contain a therapeutically effective amount of the selected antiinflammatory agent. Those of ordinary skill in the art can determine an amount that is therapeutically effective for the suppression of inflammation. The precise amount will depend upon the method of administration 3o and the age, weight and condition of the subject to be treated. Generally the t_ antiinflammatory agents are utilized in dosages known in the art to be therapeutically eiTective upon nasal administration.
The compositions of the invention further comprise at least one additional therapeutic agent, and thus allow the convenient administration of an antiinflammatory agent and at least one additional therapeutic agent in a single topical nasal composition. The additional therapeutical agent is suitable for topical nasal administration and is selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an anticholinergic agent, an antihistamine, an antiallergic agent, a local anesthetic and a mucolytic agent. The use ~o of an additional therapeutic agent in combination with an antiinflammatory agent provides additive and synergistic effects in the treatment of nasal and sinus conditions.
Vasoconstrictors suitable for topical nasal administration in the compositions of the present invention are oxymetazoline naphazoline, is xylometazoline, and phenylephrine. Leukotriene inhibitors include zafirlukast, a selective, competitive receptor antagonist of the three leukotrienes C4, D4, and E4;
pranlukast, a selective, competitive receptor antagonist of D4; and zileuton, a leukotriene inhibitor. A. neuramidinase inhibitor includes zanamivir {GG-167).
Suitable antihistamines are diphenhydramine, chlorpheniramine, cetirizine terfenadine, 2o fenofexadine, astemizole norastemizole, azelastine, and azatidine.
Antiallergic agents include cromolyn sodium and nedocromil levocabastine. An anticholinergic agent useful in the compositions of the present invention is ipratropium bromide.
Local topical anesthetics include dyclonine, pramoxine, and benzocaine. Mucolytic agents suitable for topical nasal administration are acetylcysteine, guaifenisin and 2s mucocysteine. The therapeutically efi:'ect amount of foregoing agents can be determined by the ordinarily skilled artisan with regard to the known use of these agents in the art and taking into account the method of administration and the age, weight and condition of the subject to be treated.
The compositions of the present invention are formulated as aqueous 3o solutions comprising an antiinflammatory agent and at least one additional therapeutic agent and further comprising a pharmaceutically acceptable nasal carrier.
Accordingly, a need exists for a convenient means of nasal administration of multiple therapeutic agents.
SUMMARY OF THE INVENTION
to The present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, an anticholinergic agent, a leukotriene inhibitor, an ~s antihistamine, an antiallergic agent, an anesthetic, and a mucolytic agent.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides topically applicable nasal compositions comprising a topical antiinflammatory agent and at least one additional therapeutic 2o agent. The present compositions are useful for the treatment of nasal and sinus conditions, for example allergic rhinitis or the common cold.
The topical antiinflammatory agents in the compositions of the present invention are corticosteroids known in the art to suppress inflammation. In a preferred embodiment the topical antiinflammatory agent is beclomethasone 2s diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate or triamcinolone acetonide. The compositions contain a therapeutically effective amount of the selected antiinflammatory agent. Those of ordinary skill in the art can determine an amount that is therapeutically effective for the suppression of inflammation. The precise amount will depend upon the method of administration 3o and the age, weight and condition of the subject to be treated. Generally the t_ antiinflammatory agents are utilized in dosages known in the art to be therapeutically eiTective upon nasal administration.
The compositions of the invention further comprise at least one additional therapeutic agent, and thus allow the convenient administration of an antiinflammatory agent and at least one additional therapeutic agent in a single topical nasal composition. The additional therapeutical agent is suitable for topical nasal administration and is selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an anticholinergic agent, an antihistamine, an antiallergic agent, a local anesthetic and a mucolytic agent. The use ~o of an additional therapeutic agent in combination with an antiinflammatory agent provides additive and synergistic effects in the treatment of nasal and sinus conditions.
Vasoconstrictors suitable for topical nasal administration in the compositions of the present invention are oxymetazoline naphazoline, is xylometazoline, and phenylephrine. Leukotriene inhibitors include zafirlukast, a selective, competitive receptor antagonist of the three leukotrienes C4, D4, and E4;
pranlukast, a selective, competitive receptor antagonist of D4; and zileuton, a leukotriene inhibitor. A. neuramidinase inhibitor includes zanamivir {GG-167).
Suitable antihistamines are diphenhydramine, chlorpheniramine, cetirizine terfenadine, 2o fenofexadine, astemizole norastemizole, azelastine, and azatidine.
Antiallergic agents include cromolyn sodium and nedocromil levocabastine. An anticholinergic agent useful in the compositions of the present invention is ipratropium bromide.
Local topical anesthetics include dyclonine, pramoxine, and benzocaine. Mucolytic agents suitable for topical nasal administration are acetylcysteine, guaifenisin and 2s mucocysteine. The therapeutically efi:'ect amount of foregoing agents can be determined by the ordinarily skilled artisan with regard to the known use of these agents in the art and taking into account the method of administration and the age, weight and condition of the subject to be treated.
The compositions of the present invention are formulated as aqueous 3o solutions comprising an antiinflammatory agent and at least one additional therapeutic agent and further comprising a pharmaceutically acceptable nasal carrier.
The formulation of pharmaceutical compositions is generally known in the art and reference can be conveniently made to standard text such as Remington's Pharmaceutical Sciences, 1985, 17th ed., Mack Publishing Co., Easton, Pennsylvania.
Preferred nasal formulations are nose drops or nasal sprays containing s a water buffered aqueous solution as a Garner. The compositions are preferably isotonic. Isotonic agents such as a sugars and sodium chloride are known in the art and may be included in the subject compositions.
The compositions of the present invention may also contain a humectant to increase viscosity and effect moisturization and ciliary vitality. Suitable ~o humectants include glycerin, polyethylene glycol, propylene glycol and mixtures thereof.
Additional agents including pharmaceutically acceptable preservatives, stabilizers, flavoring agents, and pH adjusters are known in the art and may be included in the present compositions.
is Another embodiment of the present invention provides preservative-free compositions comprising an anti-inflammatory agent and at least one additional therapeutic agent. Preservative-free compositions are preferred due to reduced sensitivity and increased patient acceptance. These can be prepared in unit dose or in systems which prevent contamination of the reservoir of solution.
zo The compositions of the present invention can be conveniently administered nasally to a human subject in dosage unit form to elicit the desired therapeutic effect of the antiinflammatory agent and the additional therapeutic agents described above. The compositions may be administered in the form of a nasal spray or nose drops. Nasal sprays may be provided as squeeze bottles or metered dose 2 s manual nasal spray pumps designed to deliver the desired dose in one or two sprays, for example. The composition may also be administered as aerosol spray formulations, for example as metered dose pressurized aerosols containing propellants such as halogenated hydrocarbons.
Preferred nasal formulations are nose drops or nasal sprays containing s a water buffered aqueous solution as a Garner. The compositions are preferably isotonic. Isotonic agents such as a sugars and sodium chloride are known in the art and may be included in the subject compositions.
The compositions of the present invention may also contain a humectant to increase viscosity and effect moisturization and ciliary vitality. Suitable ~o humectants include glycerin, polyethylene glycol, propylene glycol and mixtures thereof.
Additional agents including pharmaceutically acceptable preservatives, stabilizers, flavoring agents, and pH adjusters are known in the art and may be included in the present compositions.
is Another embodiment of the present invention provides preservative-free compositions comprising an anti-inflammatory agent and at least one additional therapeutic agent. Preservative-free compositions are preferred due to reduced sensitivity and increased patient acceptance. These can be prepared in unit dose or in systems which prevent contamination of the reservoir of solution.
zo The compositions of the present invention can be conveniently administered nasally to a human subject in dosage unit form to elicit the desired therapeutic effect of the antiinflammatory agent and the additional therapeutic agents described above. The compositions may be administered in the form of a nasal spray or nose drops. Nasal sprays may be provided as squeeze bottles or metered dose 2 s manual nasal spray pumps designed to deliver the desired dose in one or two sprays, for example. The composition may also be administered as aerosol spray formulations, for example as metered dose pressurized aerosols containing propellants such as halogenated hydrocarbons.
Claims (16)
1. A topically applicable nasal composition comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an cholinergic agent, an anesthetic and a mucolytic agent.
2. The composition of Claim 1 wherein said topical antiinflammatory agent is selected from the group consisting of beclomethasone diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate and triamcinolone acetonide.
3. The composition of Claim 1 wherein said vasoconstrictor is selected from the group consisting of oxymetazoline, naphazoline, xylometazoline, and phenylephrine.
4. The composition of Claim 1 wherein said antihistamine is selected from the group consisting of diphenhydramine, chlorpheniramine, terfenadine, azelastine, norastemizole, fexofenadine, cetirazine, astemizole and azatidine.
5. The composition of Claim 1 wherein said antiallergic agent is selected from the group consisting of cromolyn sodium, levocabastine, and nedocromil.
6. The composition of Claim 1 wherein said anticholinergic agent is ipratropium.
7. The composition of Claim 1 wherein said topical anesthetic is selected from the group consisting of dyclonine, pramosine, and benzocaine.
8. The composition of Claim 1 wherein said mucolytic agent is selected from the group consisting of acetylcysteine, guaifenesin and mucocysteine.
9. The composition of Claim 1 wherein said leukotriene inhibitor is selected from the group consisting of zafirlukast, pranlukah, and zileuton.
10. The composition of Claim 1 wherein said neuramidinace inhibitor is zanamivir.
11. A topically applicable nasal composition comprising a therapeutically effective amount of a topical antiinflammatory agent selected from the group consisting of beclomethasone diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate and triamcinolone acetonide and a therapeutically effective amount of at least one agent selected from the group consisting of oxymetazoline, phenylephrine, diphenhydramine, chlorpheniramine, terfenadine, astemizole, azatidine, cromolyn sodium, nedocromil, ipratropium bromide, dyclonine, benzocaine, acetylcysteine, guaifenesin and mucocysteine.
12. The composition of Claim 1 or 11 further comprising at least one humectant.
13. The composition of Claim 12 wherein said humectant is selected from the group consisting of glycerin, polyethylene glycol and propylene glycol.
14. The composition of Claim 1 or 11 comprising a pharmaceutically acceptable carrier.
15. The composition of Claim 1 or 11 formulated for application as a nasal spray.
16. The composition of Claim 1 or 11 formulated for application as nose drops.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4430697P | 1997-04-30 | 1997-04-30 | |
| US60/044,306 | 1997-04-30 | ||
| PCT/US1998/006483 WO1998048839A1 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2281789A1 true CA2281789A1 (en) | 1998-11-05 |
Family
ID=21931638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002281789A Abandoned CA2281789A1 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0979105A1 (en) |
| JP (1) | JP2001524108A (en) |
| CN (1) | CN1253508A (en) |
| AU (1) | AU6878098A (en) |
| BR (1) | BR9809022A (en) |
| CA (1) | CA2281789A1 (en) |
| IL (1) | IL131492A0 (en) |
| WO (1) | WO1998048839A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ295461B6 (en) * | 1997-08-26 | 2005-08-17 | Aventis Pharmaceuticals Inc. | Pharmaceutical preparation in the form of bilayer tablet |
| SK286103B6 (en) * | 1997-12-23 | 2008-03-05 | Schering Corporation | Pharmaceutical composition for treating respiratory and skin diseases, comprising at least on leucotriene antagonist and at least one antihistamine, and the use of the same |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| GB9822170D0 (en) * | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| IT1313567B1 (en) * | 1999-07-27 | 2002-09-09 | Zambon Spa | USE OF N-ACETYL-CISTEIN FOR THE PREPARATION OF TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALLERGIC PATHOLOGIES OF |
| DE10007203A1 (en) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist |
| DE60209511T2 (en) | 2001-09-18 | 2006-10-05 | Nycomed Danmark Aps | COMPOSITIONS FOR TREATING SNORING CONTAINING IPRATROPY AND XYLOMETAZOLIN |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| WO2004000272A1 (en) * | 2002-06-20 | 2003-12-31 | Novartis Consumer Health S.A. | Nasal compositions comprising a mucopolysaccharide and propylene glycol |
| BR0313611A (en) | 2002-08-30 | 2005-06-21 | Altana Pharma Ag | Use of the ciclesonide and antihistamine combination for the treatment of allergic rhinitis |
| AU2003254429A1 (en) * | 2003-08-06 | 2005-02-25 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| KR20070104884A (en) | 2004-11-24 | 2007-10-29 | 메드포인트 헬쓰케어 인크. | Compositions comprising azelastine and methods of use thereof |
| PL1863476T3 (en) * | 2005-03-16 | 2016-07-29 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| WO2007023935A1 (en) * | 2005-08-26 | 2007-03-01 | Meiji Dairies Corporation | Anti-allergic agent |
| US8637469B2 (en) | 2006-07-11 | 2014-01-28 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
| JP2008143845A (en) * | 2006-12-11 | 2008-06-26 | Hoshienu Seiyaku Kk | Nasal drop composition and nasal drop spraying tool |
| US8709508B2 (en) * | 2012-05-25 | 2014-04-29 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
| CN104667256B (en) * | 2015-03-18 | 2017-05-03 | 江苏威克斯医疗科技有限公司 | Nasal cavity mucosa cilium nursing flushing fluid and application thereof |
| CN107753485A (en) * | 2017-11-28 | 2018-03-06 | 赵永宏 | A kind of pharmaceutical composition for having nose congestion and anesthetic effect concurrently and its application |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482015A (en) * | 1965-02-08 | 1969-12-02 | Merck & Co Inc | Aerosol composition of phenylephrine tartrate and the production of such |
| US4053628A (en) * | 1971-05-12 | 1977-10-11 | Fisons Limited | Composition |
| US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| JPH0753671B2 (en) * | 1985-12-26 | 1995-06-07 | 積水化学工業株式会社 | Transdermal / transmucosal preparation |
| DE69229880T2 (en) * | 1991-11-19 | 2000-05-04 | The University Of Virginia Patent Foundation, Charlottesville | COMBINED VIRUSTATIC ANTIMEDIATOR TREATMENT (COVAM) OF ORDINARY COOLS |
| AU7604094A (en) * | 1993-09-07 | 1995-03-27 | Procter & Gamble Company, The | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| AU6290396A (en) * | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
| WO1997001337A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
| DE19532714A1 (en) * | 1995-09-05 | 1997-03-06 | Bayer Ag | Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids |
| EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
-
1998
- 1998-04-02 AU AU68780/98A patent/AU6878098A/en not_active Abandoned
- 1998-04-02 EP EP98914420A patent/EP0979105A1/en not_active Withdrawn
- 1998-04-02 BR BR9809022-4A patent/BR9809022A/en not_active Application Discontinuation
- 1998-04-02 JP JP54699898A patent/JP2001524108A/en active Pending
- 1998-04-02 WO PCT/US1998/006483 patent/WO1998048839A1/en not_active Application Discontinuation
- 1998-04-02 CN CN98804579A patent/CN1253508A/en active Pending
- 1998-04-02 IL IL13149298A patent/IL131492A0/en unknown
- 1998-04-02 CA CA002281789A patent/CA2281789A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1253508A (en) | 2000-05-17 |
| AU6878098A (en) | 1998-11-24 |
| WO1998048839A1 (en) | 1998-11-05 |
| EP0979105A1 (en) | 2000-02-16 |
| IL131492A0 (en) | 2001-01-28 |
| BR9809022A (en) | 2000-08-01 |
| JP2001524108A (en) | 2001-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2281789A1 (en) | Topical nasal antiinflammatory compositions | |
| EP1227812B1 (en) | Topical nasal treatment using desloratadine and mometasone furoate | |
| AU651089B2 (en) | Treatment of sinus headache | |
| JP4500045B2 (en) | Composition for the treatment of the common cold | |
| JPH11511758A (en) | Intranasal spray containing nasal steroids and antihistamines | |
| EP0780127A1 (en) | A nasal spray containing a steroid and a antihistamine | |
| US20050281751A1 (en) | Directed intranasal administration of pharmaceutical agents | |
| US9301936B2 (en) | Pharmaceutical formulations of tranexamic acid and their use | |
| JP4521117B2 (en) | Medications for treating migraine, cluster headache, tension headache, headache associated with vascular disease, tinnitus or muscular headache | |
| AU2012216890A1 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| US20020193417A1 (en) | Nasal solutions | |
| EP2349337A1 (en) | Formulations for the treatment of acute herpes zoster pain | |
| RU2472499C2 (en) | Therapeutic agent containing combination of active substances containing pantothenic acid or its derivatives for treating allergic symptoms | |
| JPH0269413A (en) | Treatment of allergic rhinitis | |
| RU2005135332A (en) | NASAL PHARMACEUTICAL COMPOSITIONS AND WAYS OF THEIR APPLICATION | |
| EP1835911B1 (en) | Therapeutic compositions for intranasal administration of ketorolac | |
| JPS6034909A (en) | Snore controlling agent | |
| US4385048A (en) | Methods for the treatment of nasal hypersecretion | |
| US20110201582A1 (en) | Method and composition for treatment of skin conditions | |
| McAllen et al. | Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis | |
| ES2340777T3 (en) | METHOD OF TREATMENT OF ACUTE RHINOSINUSITIS. | |
| US7332528B2 (en) | DRI nasal sprays | |
| MXPA99007597A (en) | Topical nasal antiinflammatory compositions | |
| EA009990B1 (en) | Synergistic combination comprising roflumilast and (r,r) -formoterol | |
| Martini et al. | Nasal and pulmonary drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20020402 |